| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 13.09.2018 og
angivet som gældende fra 12.09.2018 (2229
dage). |
Ingen historik.
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 13.09.2018 og
angivet som gældende fra 12.09.2018 (2229
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 24.02.2020 og
angivet som gældende fra 24.02.2020 (1699
dage). |
| Historik | Start | Stop |
|---|
| false | 24.02.2020 | |
| true | 12.09.2018 | 23.02.2020 |
| Kontaktoplysninger | | info@octarinebio.com. |
| Sidst opdateret den 13.09.2019 og
angivet som gældende fra 13.09.2019 (1863
dage). |
| Historik | Start | Stop |
|---|
| info@octarinebio.com | 13.09.2019 | |
| nethajigallage@gmail.com | 23.09.2018 | 12.09.2019 |
| gallagenethaji@gmail.com | 12.09.2018 | 22.09.2018 |
| Telefonnummer | | 27639353. |
| Sidst opdateret den 13.09.2018 og
angivet som gældende fra 12.09.2018 (2229
dage). |
Ingen historik.
| Navne | | Octarine Bio ApS. |
| Sidst opdateret den 20.10.2020 og
angivet som gældende fra 14.10.2020 (1466
dage). |
| Historik | Start | Stop |
|---|
| Octarine Bio ApS | 14.10.2020 | |
| Octarine Bio IVS | 12.09.2018 | 13.10.2020 |
| Binavne | | Octarine ApS. |
| Sidst opdateret den 20.10.2020 og
angivet som gældende fra 15.10.2020 (1465
dage). |
| Historik | Start | Stop |
|---|
| Octarine ApS | 15.10.2020 | |
| Octarine IVS | 12.09.2018 | 14.10.2020 |
| Tegningsregel | | Selskabet tegnes af to direktører eller en direktør sammen med to bestyrelsesmedlemmer. |
| Sidst opdateret den 27.03.2023 og
angivet som gældende fra 27.03.2023 (572
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 2 direktører + 2 bestyrelsesmedlemmer |
| 1 direktør + 2 bestyrelsesmedlemmer |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af to direktører eller en direktør sammen med to bestyrelsesmedlemmer | 27.03.2023 | |
| Selskabet tegnes af direktionen | 12.09.2018 | 26.03.2023 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Ri Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:44528045
Beskrivelse af revisor:State Authorized Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor's responsibilities for the audit of the financial statements” section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Octarine Bio ApS for the financial year 1 January - 31 December 2023, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared under the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2023 and of the results of the company's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on management's review
Management is responsible for management's review.
Our opinion on the financial statements døs not cover management's review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | www.octarinebio.com. |
| Sidst opdateret den 05.08.2022 og
angivet som gældende fra 05.08.2022 (806
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration